Geoff Meacham

Biogen Inc (NASDAQ: BIIB) shares saw a nice 40% bump Wednesday following the release of FDA briefing document prepared for Friday's Adcom meeting to discuss aducanumab BLA. Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $357 price target. BofA Securities...

Biogen Inc (NASDAQ: BIIB) shares jumped more than 40% on Wednesday after the company received a favorable FDA briefing related to the company’s investigational Alzheimer's drug aducanumab. Despite the huge bullish move, at least one trader is speculating Biogen’s big run may be just...

Eli Lilly And Co’s (NYSE: LLY) third-quarter results show the persisting impact of COVID-19 and pricing headwinds, according to BofA Securities. The Eli Lilly Analyst: Geoff Meacham maintained a Buy rating on Eli Lilly with a $180 price target.  The Eli Lilly Thesis: The downbeat third-...

Gilead Sciences, Inc. (NASDAQ: GILD) faces a regulatory setback as filgotinib,  an investigational drug it is co-developing with GALAPAGOS NV/S ADR (NASDAQ: GLPG), received a thumbs-down from the FDA. The Gilead Analyst: BofA Securities analyst Geoff Meacham reiterated a Neutral...

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for...

Moderna Inc (NASDAQ: MRNA) shares were bulldozing their way toward record highs Wednesday in reaction to the publication in the New England Journal of Medicine of detailed interim Phase 1 data for mRNA-1273, its SARS-CoV2 vaccine candidate. The Moderna Analysts: BofA Securities analyst...

Gilead Sciences, Inc. (NASDAQ: GILD) received FDA Emergency Use Authorization for remdesivir in early May as a treatment option for COVID-19 in adults and pediatric patients who are hospitalized with severe disease. The company has since commenced studies for an inhaled formulation...

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports...

Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have blockbuster potential, according to BofA Securities.  Brace For Bristol-Myers' ‘Big 7' Bristol-Myers...

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing. An analyst at BofA Securities said Friday that now is the time to go from defensive to offensive in the sector, as quarantines are winding down in...

The S&P 500 has rallied hard off its March lows, but the index remains down 12.9% year-to-date overall. The near-term economic outlook amid the COVID-19 shutdown is still unclear, creating a lot of uncertainty on Wall Street. The International Monetary Fund recently cut its 2020 global economic...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Gilead Sciences, Inc. (NASDAQ: GILD) announced publication Friday of data in the New England Journal of Medicine from a small cohort of COVID-19 patients who were treated with its remdesivir through compassionate use. The Gilead Analysts BofA Securities analyst Geoff Meacham maintained...

Gilead Sciences, Inc. (NASDAQ: GILD) shares spiked about 6.6% Wednesday in reaction to a Piper Sandler note that suggested the biopharma's remdesivir could be approved for COVID-19.  An analyst at BofA Securities isn't convinced of remdesivir's potential. The Gilead Analyst...